MERCK
MRKDrugs in Pipeline
603
Phase 3 Programs
380
Upcoming Catalysts
73
Next Catalyst
Mar 5, 2026
25dMarket Overview
Stock performance and market intelligence
73 upcoming, 2 past
Intismeran autogene Phase 3 Results Expected
Primary completion for Intismeran autogene trial (NCT06295809) in Carcinoma, Squamous Cell
SourcePembrolizumab Phase 3 Results Expected
Primary completion for Pembrolizumab trial (NCT06295809) in Carcinoma, Squamous Cell
SourceBelzutifan Phase 2 Results Expected
Primary completion for Belzutifan trial (NCT03401788) in VHL - Von Hippel-Lindau Syndrome
Sourcefavezelimab/pembrolizumab Phase 2 Results Expected
Primary completion for favezelimab/pembrolizumab trial (NCT06036836) in Solid Tumor
Sourcelenvatinib Phase 2 Results Expected
Primary completion for lenvatinib trial (NCT06036836) in Solid Tumor
Sourcepembrolizumab Phase 2 Results Expected
Primary completion for pembrolizumab trial (NCT06036836) in Solid Tumor
SourceFrespaciguat Phase 2 Results Expected
Primary completion for Frespaciguat trial (NCT05612035) in Pulmonary Hypertension
SourcePembrolizumab/Quavonlimab Phase 2 Results Expected
Primary completion for Pembrolizumab/Quavonlimab trial (NCT04626479) in Carcinoma, Renal Cell
SourceLenvatinib Phase 2 Results Expected
Primary completion for Lenvatinib trial (NCT04626479) in Carcinoma, Renal Cell
SourceMK-4830 Phase 2 Results Expected
Primary completion for MK-4830 trial (NCT04626518) in Carcinoma, Renal Cell
SourceBelzutifan Phase 2 Results Expected
Primary completion for Belzutifan trial (NCT04626479) in Carcinoma, Renal Cell
SourcePembrolizumab Phase 2 Results Expected
Primary completion for Pembrolizumab trial (NCT04626479) in Carcinoma, Renal Cell
SourceVibostolimab/Pembrolizumab Phase 2 Results Expected
Primary completion for Vibostolimab/Pembrolizumab trial (NCT04626479) in Carcinoma, Renal Cell
SourceFavezelimab/Pembrolizumab Phase 2 Results Expected
Primary completion for Favezelimab/Pembrolizumab trial (NCT04626479) in Carcinoma, Renal Cell
SourcePembrolizumab (+) Berahyaluronidase alfa Phase 3 Results Expected
Primary completion for Pembrolizumab (+) Berahyaluronidase alfa trial (NCT06698042) in Lung Cancer
SourceOlaparib Phase 2 Results Expected
Primary completion for Olaparib trial (NCT04123366) in Solid Tumors
SourceSacituzumab tirumotecan Phase 2 Results Expected
Primary completion for Sacituzumab tirumotecan trial (NCT06637423) in Non-Muscle Invasive Bladder Cancer
SourceRescue medication Phase 2 Results Expected
Primary completion for Rescue medication trial (NCT06637423) in Non-Muscle Invasive Bladder Cancer
SourceCisplatin Phase 3 Results Expected
Primary completion for Cisplatin trial (NCT04380636) in Lung Neoplasms
SourceRaludotatug Deruxtecan (R-DXd) Phase 2 Results Expected
Primary completion for Raludotatug Deruxtecan (R-DXd) trial (NCT06864169) in Gastrointestinal Cancer
SourceEtoposide Phase 3 Results Expected
Primary completion for Etoposide trial (NCT04380636) in Lung Neoplasms
SourcePemetrexed Phase 3 Results Expected
Primary completion for Pemetrexed trial (NCT04380636) in Lung Neoplasms
SourceCarboplatin Phase 3 Results Expected
Primary completion for Carboplatin trial (NCT04380636) in Lung Neoplasms
SourcePaclitaxel Phase 3 Results Expected
Primary completion for Paclitaxel trial (NCT04380636) in Lung Neoplasms
SourcePembrolizumab Phase 3 Results Expected
Primary completion for Pembrolizumab trial (NCT06698042) in Lung Cancer
SourceOlaparib Phase 3 Results Expected
Primary completion for Olaparib trial (NCT04380636) in Lung Neoplasms
SourceBelzutifan Phase 2 Results Expected
Primary completion for Belzutifan trial (NCT05468697) in Renal Cell Carcinoma
SourcePalbociclib Phase 2 Results Expected
Primary completion for Palbociclib trial (NCT05468697) in Renal Cell Carcinoma
SourcePembrolizumab Phase 2 Results Expected
Primary completion for Pembrolizumab trial (NCT04123366) in Solid Tumors
SourceIV Tulisokibart Phase 3 Results Expected
Primary completion for IV Tulisokibart trial (NCT06052059) in Ulcerative Colitis
SourceSC Tulisokibart Phase 3 Results Expected
Primary completion for SC Tulisokibart trial (NCT06052059) in Ulcerative Colitis
Sourcepemetrexed Phase 3 Results Expected
Primary completion for pemetrexed trial (NCT05298423) in Carcinoma, Non-Small-Cell Lung
Sourcepembrolizumab/vibostolimab Phase 3 Results Expected
Primary completion for pembrolizumab/vibostolimab trial (NCT05298423) in Carcinoma, Non-Small-Cell Lung
Sourceetoposide Phase 3 Results Expected
Primary completion for etoposide trial (NCT05298423) in Carcinoma, Non-Small-Cell Lung
SourceCisplatin Phase 3 Results Expected
Primary completion for Cisplatin trial (NCT04634877) in Endometrial Neoplasms
SourceCarboplatin Phase 3 Results Expected
Primary completion for Carboplatin trial (NCT04634877) in Endometrial Neoplasms
SourceDocetaxel Phase 3 Results Expected
Primary completion for Docetaxel trial (NCT04634877) in Endometrial Neoplasms
SourcePembrolizumab Phase 3 Results Expected
Primary completion for Pembrolizumab trial (NCT04634877) in Endometrial Neoplasms
SourceCisplatin (as radiosensitizer) Phase 3 Results Expected
Primary completion for Cisplatin (as radiosensitizer) trial (NCT04634877) in Endometrial Neoplasms
SourcePaclitaxel Phase 3 Results Expected
Primary completion for Paclitaxel trial (NCT04634877) in Endometrial Neoplasms
SourceNemtabrutinib Phase 2 Results Expected
Primary completion for Nemtabrutinib trial (NCT03162536) in Lymphoma, B-Cell
SourceBelzutifan Phase 3 Results Expected
Primary completion for Belzutifan trial (NCT05239728) in Carcinoma, Renal Cell
SourcePembrolizumab Phase 3 Results Expected
Primary completion for Pembrolizumab trial (NCT04736706) in Carcinoma, Renal Cell
SourcePembrolizumab/Quavonlimab Phase 3 Results Expected
Primary completion for Pembrolizumab/Quavonlimab trial (NCT04736706) in Carcinoma, Renal Cell
SourceLenvatinib Phase 3 Results Expected
Primary completion for Lenvatinib trial (NCT04736706) in Carcinoma, Renal Cell
SourceBelzutifan Phase 3 Results Expected
Primary completion for Belzutifan trial (NCT04736706) in Carcinoma, Renal Cell
SourceLenvatinib Phase 2 Results Expected
Primary completion for Lenvatinib trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
SourceSupportive care measures Phase 2 Results Expected
Primary completion for Supportive care measures trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
SourceAntihistamine Phase 2 Results Expected
Primary completion for Antihistamine trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
SourceSacituzumab tirumotecan Phase 2 Results Expected
Primary completion for Sacituzumab tirumotecan trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
SourceMK-4830 Phase 2 Results Expected
Primary completion for MK-4830 trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
SourcePembrolizumab Phase 2 Results Expected
Primary completion for Pembrolizumab trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
SourcePaclitaxel Phase 2 Results Expected
Primary completion for Paclitaxel trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
SourceTulisokibart Phase 2 Results Expected
Primary completion for Tulisokibart trial (NCT06956235) in Hidradenitis Suppurativa
SourcePosaconazole IV 6 mg/kg Phase 2 Results Expected
Primary completion for Posaconazole IV 6 mg/kg trial (NCT04665037) in Invasive Fungal Infection
SourcePembrolizumab Phase 3 Results Expected
Primary completion for Pembrolizumab trial (NCT04700124) in Bladder Cancer
SourceEnfortumab vedotin (EV) Phase 3 Results Expected
Primary completion for Enfortumab vedotin (EV) trial (NCT04700124) in Bladder Cancer
SourceRamucirumab Phase 2 Results Expected
Primary completion for Ramucirumab trial (NCT06445972) in Gastroesophageal Junction
SourceMK-1167 Phase 2 Results Expected
Primary completion for MK-1167 trial (NCT06721156) in Alzheimer Disease
SourceSacituzumab tirumotecan Phase 3 Results Expected
Primary completion for Sacituzumab tirumotecan trial (NCT06356311) in Gastroesophageal Cancer
SourceTrifluridine-Tipiracil Phase 3 Results Expected
Primary completion for Trifluridine-Tipiracil trial (NCT06356311) in Gastroesophageal Cancer
SourceSupportive care measures Phase 3 Results Expected
Primary completion for Supportive care measures trial (NCT06356311) in Gastroesophageal Cancer
SourceRescue medication Phase 3 Results Expected
Primary completion for Rescue medication trial (NCT06356311) in Gastroesophageal Cancer
SourcePaclitaxel Phase 3 Results Expected
Primary completion for Paclitaxel trial (NCT06356311) in Gastroesophageal Cancer
SourceSacituzumab Govitecan Phase 3 Results Expected
Primary completion for Sacituzumab Govitecan trial (NCT05609968) in Carcinoma, Non-Small-Cell Lung
SourceSacituzumab Tirumotecan (sac-TMT) Phase 2 Results Expected
Primary completion for Sacituzumab Tirumotecan (sac-TMT) trial (NCT06469944) in Gastroesophageal Junction
Sourcepembrolizumab Phase 2 Results Expected
Primary completion for pembrolizumab trial (NCT03407144) in Hodgkin Lymphoma
SourceFluorouracil (5-FU) Phase 3 Results Expected
Primary completion for Fluorouracil (5-FU) trial (NCT04241185) in Urinary Bladder Neoplasms
SourcePembrolizumab Phase 3 Results Expected
Primary completion for Pembrolizumab trial (NCT04241185) in Urinary Bladder Neoplasms
SourceCisplatin Phase 3 Results Expected
Primary completion for Cisplatin trial (NCT04241185) in Urinary Bladder Neoplasms
Source5-FU Phase 3 Results Expected
Primary completion for 5-FU trial (NCT04210115) in Esophageal Squamous Cell Carcinoma (ESCC)
Sourcelevoleucovorin Phase 3 Results Expected
Primary completion for levoleucovorin trial (NCT04210115) in Esophageal Squamous Cell Carcinoma (ESCC)
Sourceleucovorin Phase 3 Results Expected
Primary completion for leucovorin trial (NCT04210115) in Esophageal Squamous Cell Carcinoma (ESCC)
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
MK0966; Rofecoxib / Duration of Treatment: 156 weeks
Colorectal Adenoma
V503 Vaccine
Papillomavirus Infections
Saizen® A
Children Born With Serious Intra-uterine Growth Retardation
Modified Process Hepatitis B Vaccine
Hepatitis B
MK0557
Obesity
Pembrolizumab Formulated with Berahyaluronidase Alfa
Metastatic Non-small Cell Lung Cancer
Pneumovax™ 23
Pneumococcal Infections
Posaconazole
Mycoses
Metformin - Rescue
Diabetes Mellitus, Type 2
Infanrix® hexa
Varicella
IV Tulisokibart
Crohn's Disease
Daptomycin 4 mg/kg
Staphylococcal Infection
Gonalef® (Follitropin alfa)
Infertility
Fluconazole
Leukopenia
MK0826, ertapenem sodium / Duration of Treatment - 24 weeks
Foot Infections in Diabetic Patients
Naproxen
Endometriosis-related Pain
fidaxomicin
Clostridium Difficile-Associated Diarrhea (CDAD)
Zoster Vaccine, Live
Herpes Zoster
losartan potassium
Hypertension
anacetrapib
Coronary Heart Disease (CHD)
dorzolamide hydrochloride (+) timolol maleate
Glaucoma
rofecoxib
Prostate Cancer
ProQuad®
Measles
RotaTeq™, rotavirus vaccine, live, oral, pentavalent
Rotavirus Infections
Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)
Papillomavirus Infections
Infliximab + methotrexate (IFX + MTX)
Arthritis, Psoriatic
Rebif New Formulation + prophylactic Ibuprofen
Relapsing Multiple Sclerosis
PPSV23
Pneumococcal Disease
Boceprevir
Chronic Hepatitis C Genotype 1
Esmirtazapine
Insomnia
hydrochlorothiazide (HCTZ)
Hypertension
PNEUMOVAX™23
Pneumococcal Infections
Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)
Head and Neck Cancer
Ertapenem sodium
Infection; Diabetic Foot
MK0826, ertapenem sodium / Duration of Treatment: 14 Days
Infection
Prednisone
Prostatic Neoplasms
pneumococcal 23v polysaccharide vaccine
Pneumococcal Infection
niacin (+) laropiprant (+) simvastatin
Primary Hypercholesterolemia
Modified Process Hepatitis B Vaccine (Experimental)
Hepatitis B
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
Papillomavirus Infections
V212
Herpes Zoster
Dexamethasone 4 mg
Non-Small-Cell Lung Carcinoma
Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)
Hepatitis C, Chronic
Open-label Metformin
Type 2 Diabetes
Olaparib
Ovarian Cancer
Pembrolizumab 400 mg
Small Cell Lung Cancer
RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
Vomiting
docetaxel
Endometrial Neoplasms
Rescue Medications
Cervical Cancer
MTX
Arthritis, Rheumatoid
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Cervical Cancer
V920 Consistency Lot A
Prevention of Ebola Infection
Peginterferon alfa-2a
Hepatitis C, Chronic
Letermovir
Cytomegalovirus Infection
Sacituzumab tirumotecan
Colorectal Cancer
V232 Modified Process Hepatitis B Vaccine: Lot A
Hepatitis B Infection
PCV13
Pneumococcal Infections
Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)
Varicella
Ribavirin
Hepatitis C
Anacetrapib 100 mg
Hypercholesterolemia
Gardasil™
Papillomavirus Infections
Tobramycin
Bacterial Conjunctivitis
Pegylated interferon alfa-2b
Hepatitis C
Basal Insulin
Type 2 Diabetes Mellitus
0.9% sodium chloride (NaCl)
Anesthesia
sac-TMT
Non-small Cell Lung Cancer
Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
Chronic Hepatitis C
Org 50081
Insomnia
HBVAXPRO™
Hepatitis B
VARIVAX™
Varicella
SC Tulisokibart
Ulcerative Colitis
Insulin
Type 2 Diabetes Mellitus
Vericiguat
Heart Failure
DAPTACEL™
Bacterial Infections
etoposide
Carcinoma, Non-Small-Cell Lung
IMI/REL FDC
Hospital-Acquired Bacterial Pneumonia
Vicriviroc
HIV Infections
Molnupiravir
Coronavirus Disease (COVID-19)
losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)
Hypertension
ertapenem sodium (MK0826)
Urinary Tract Infection
Pegylated liposomal doxorubicin (SCH 200746)
Breast Cancer
Enzalutamide
Metastatic Hormone-Sensitive Prostate Cancer
peginterferon alfa-2b (SCH 54031)
Chronic Hepatitis C
Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin
Hepatitis C, Chronic
Pembrolizumab SC
Non-Small Cell Lung Cancer
ISL
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
TR-701 FA
Skin and Subcutaneous Tissue Bacterial Infections
Neostigmine
Anesthesia
5-Fluorouracil
Uterine Cervical Neoplasms
CB-183,315
Clostridium Difficile Infection
Pioglitazone
Type 2 Diabetes Mellitus
ceftriaxone sodium
Infection
PCV15
Pneumonia, Pneumococcal
eribulin
Metastatic Triple Negative Breast Cancer
Sitagliptin 50 mg
Type 2 Diabetes Mellitus
Preservative-Free Tafluprost or vehicle
Glaucoma
Preladenant 2 mg tablet
Parkinson Disease
Recombinant human luteinizing hormone (r-hLH)
Hypogonadism
Experimental: V503
Cervical Cancer
Peginterferon alfa-2b (PegIntron, SCH 54031)
Hepatitis D, Chronic
RNF
Multiple Sclerosis
H1 receptor antagonist
Ovarian Cancer
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
Cervical Cancer
Telcagepant potassium 150 mg
Migraine
Hepatitis A Vaccine, Purified Inactivated (VAQTA™)
Hepatitis A Virus Infection
Vancomycin
Clostridium Difficile Infection
Ondansetron
Chemotherapy-Induced Nausea and Vomiting (CINV)
Anagrelide
Essential Thrombocythemia
ULO
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Telcagepant 140 mg
Migraines
Telcagepant 300 mg soft gel capsules
Migraine
Leucovorin
Gastric Cancer
Rotarix™
Pneumococcal Infections
MK-3415
Clostridium Difficile Infection
Leucovorin/ levoleucovorin
Metastatic Colorectal Cancer
epinastine nasal spray, low concentration, low dose volume
Seasonal Allergic Rhinitis
Letermovir tablet
Cytomegalovirus Infection
peginterferon alfa-2b (PEG2b) (SCH 54031)
Hepatitis C, Chronic
Prulifloxacin
Acute Gastroenteritis in Adult Travelers
Efalizumab
Moderate to Severe Psoriasis
Suvorexant High Dose (HD)
Primary Insomnia
FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Sacituzumab Govitecan
Carcinoma, Non-Small-Cell Lung
Valganciclovir
CMV Disease
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Intra-abdominal Infection
Uridine 5'-Triphosphate (UTP) Solution for Inhalation
Lung Cancer
Glycopyrrolate
Surgical Procedures, Elective
Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)
Rotavirus
MK0524A, /Duration of Treatment : 4 Weeks
Flushing
Rebif® New Formulation (IFN-beta-1a, RNF)
Multiple Sclerosis, Relapsing-Remitting
ART
HIV-1 Infection
Sitagliptin plus metformin
Type 2 Diabetes Mellitus
Linezolid
Pneumonia
liposomal doxorubicin
Breast Neoplasms
diquafosol tetrasodium (INS365) ophthalmic solution
Dry Eye Disease
REBETOL (ribavirin; SCH 18908)
Hepatitis C, Chronic
AzaSite
Bacterial Conjunctivitis
rosiglitazone
Type 2 Diabetes Mellitus
VARIVAX™ New Seed Process
Varicella
levoleucovorin
Esophageal Squamous Cell Carcinoma (ESCC)
Cetuximab plus Platinum-based Doublet Chemotherapy
Non-Small Cell Lung Cancer (NSCLC)
ribavirin (SCH 18908)
Hepatitis C, Chronic
MK-0524B
Primary Hypercholesterolemia
Cyclophosphamide
Diffuse Large B-Cell Lymphoma
lovastatin
Atherosclerosis
MMRV (AMP)
Measles
Folinic Acid
Metastatic Colorectal Cancer
Lamivudine
HIV Infections
RotaTeq™ experimental formulation
Rotavirus Gastroenteritis
Ifinatamab Deruxtecan
Castration-Resistant Prostatic Cancer
Insulin Glargine
Type 2 Diabetes Mellitus
Bomedemstat
Thrombocythemia, Essential
Sulfonylurea
Type 2 Diabetes Mellitus
Pembrolizumab (MK-3475)
Merkel Cell Carcinoma
Hydroxyurea
Essential Thrombocythemia
Zidovudine
HIV Infections
Glimepiride
Type 2 Diabetes Mellitus
MK-0518
HIV Infections
Grazoprevir 100mg / Elbasvir 50 mg FDC
Chronic Hepatitis C Virus
Kuvan®
Phenylketonuria
Pioglitazone hydrochloride
Type 2 Diabetes Mellitus
Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
Chronic Hepatitis C
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
Herpes Zoster
Ertugliflozin 10 mg
Type 2 Diabetes Mellitus
Peg-interferon alfa-2b
Hepatitis C, Chronic
Rotateq™
Rotavirus Infections
MK-8527
Human Immunodeficiency Virus (HIV)
PCV15 - Part B
Pneumococcal Disease
Zilovertamab vedotin
B-cell Acute Lymphoblastic Leukemia
Doravirine, Tenofovir, Lamivudine
HIV-1 Infection
Pembrolizumab/Quavonlimab
Colorectal Cancer
MK-5172A
Chronic Hepatitis C
PegIntron (peginterferon alfa-2b; SCH 54031)
Hepatitis
Grazoprevir
Chronic Hepatitis C (CHC)
PEG-Intron
Hepatitis C
Granulocyte Colony-Stimulating Factor (G-CSF)
DLBCL
Emtricitabine/tenofovir disoproxil (FTC/TDF)
Human Immunodeficiency Virus (HIV)
peg-Interferon alfa-2a
Hepatitis C, Chronic
Zoster Vaccine, Live (AMP)
Herpes Zoster
Cisplatin/Carboplatin
Carcinoma, Squamous Cell of Head and Neck
Fosaprepitant dimeglumine
Chemotherapy-Induced Nausea and Vomiting (CINV)
Aprepitant 125 mg
Chemotherapy Induced Nausea and Vomiting
Human Papillomavirus (HPV) 16 Monovalent
Cervical Cancer
Atropine
Anesthesia, General
Glycemic Rescue 1
Diabetes Mellitus
Axitinib
Renal Cell Carcinoma
Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.
Type 2 Diabetes Mellitus
Androgen Deprivation Therapy (ADT)
Metastatic Hormone-Sensitive Prostate Cancer
ZOSTAVAX
Herpes Zoster
Dacarbazine
Classical Hodgkin Lymphoma
Cisplatin (as radiosensitizer)
Endometrial Neoplasms
Boceprevir (BOC)
Chronic Hepatitis C
Intismeran autogene
Bladder Cancer
MK0869, aprepitant
Postoperative Nausea and Vomiting
Cabozantinib
Renal Cell Carcinoma (RCC)
Voriconazole
Aspergillosis
Short ragweed pollen allergen extract
Rhinitis, Allergic, Seasonal
MK0803, lovastatin
Hypercholesterolemia
Trifluridine-Tipiracil
Gastroesophageal Cancer
Rescue medication
Non-Muscle Invasive Bladder Cancer
Tisotumab Vedotin
Cervical Cancer
niacin (+) laropiprant
Hypercholesterolemia
TAS-102 (trifluridine and tipiracil)
Colorectal Neoplasms
Diquafosol tetrasodium ophthalmic solution, 2%
Dry Eye Disease
favezelimab/pembrolizumab
Hodgkin Lymphoma
Golimumab
Spondylitis, Ankylosing
TAS-102
Colorectal Cancer
Infliximab + methotrexate (MTX)
Arthritis, Rheumatoid
Gefapixant 15 mg BID
Chronic Cough
Standard of Care (SOC)
Solid Tumors
Enalapril
Hypertension
Tedizolid phosphate
Acute Bacterial Skin and Skin Structure Infections
SC golimumab
Arthritis, Rheumatoid
Sitagliptin 100 mg
Type 2 Diabetes Mellitus
Voglibose
Diabetes Mellitus, Non-Insulin-Dependent
ER-niacin
Primary Hypercholesterolaemia
MK-1293
Type 1 Diabetes Mellitus
CXA-201 and metronidazole
Complicated Intra-abdominal Infection
PAR-101/OPT-80
Clostridium Infections
ZOSTAVAX™
Herpes Zoster
cetuximab + cisplatin + vinorelbine
Non Small Cell Lung Cancer (NSCLC)
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Type 2 Diabetes Mellitus (T2DM)
ER niacin (+) laropiprant (ERN/LRPT)
Dyslipidemia
Vancomycin (or equivalent)
Acute Hematogenous Osteomyelitis
Elbasvir
Hepatitis C
Zanzalintinib
Renal Cell Carcinoma
methotrexate
Psoriasis
5-FU
Metastatic Esophageal Squamous Cell Carcinoma
Vorinostat
Mesothelioma
Oxaliplatin
Colorectal Neoplasms
rolofylline
Heart Failure, Congestive
Gardasil
Papillomavirus Infections
Cetrorelix acetate
Polycystic Ovarian Syndrome
MK0966 / Duration of Treatment: 1 Days
Pain, Postoperative Arthroscopy
RotaTeq (V260)
Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9
Aprepitant
Post-operative Nausea
Frespaciguat
Pulmonary Hypertension
Pembrolizumab/Vibostolimab
Lung Neoplasms
caspofungin acetate
Fungal Infection
MK0826, ertapenem sodium
Infections
Pembrolizumab (+) Berahyaluronidase alfa
Lung Cancer
Paclitaxel
Metastatic Non-Small Cell Lung Cancer
MK-6072
Clostridium Difficile Infection
Gliclazide
Type 2 Diabetes Mellitus
MK-0524A
Hypercholesteremia
Supportive care measures
Non-small Cell Lung Cancer (NSCLC)
ZOSTAVAX™ (concomitant)
Herpes Zoster
Doxorubicin
Breast Neoplasms
MK0974 50 mg
Migraine
Vitamin D3
Osteoporosis
MK0869, aprepitant / Duration of Treatment: 3 days
Nausea
neostigmine and glycopyrrolate or atropine
Neuromuscular Blockade
INS365 Ophthalmic Solution
Keratoconjunctivitis Sicca
Glipizide
Diabetes Mellitus, Type 2
Dexamethasone
Metastatic Castration-resistant Prostate Cancer (mCRPC)
M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
Measles
regorafenib
Colorectal Cancer
sitagliptin phosphate (+) metformin hydrochloride
Type 2 Diabetes Mellitus
V110, pneumococcal vaccine polyvalent
Healthy
Reformulated Raltegravir
HIV Infection
Background PAH Therapy
Pulmonary Arterial Hypertension
BIC/FTC/TAF
HIV-1 Infection
MK0991, caspofungin acetate / Duration of Treatment:
Fungal Infection
daptomycin
Pneumonia, Bacterial
Ertugliflozin 5 mg
Type 2 Diabetes Mellitus
Carboplatin
Carcinoma, Squamous Cell, Non-small-cell Lung
alvimopan
Ileus
pembrolizumab
Non-small Cell Lung Cancer
Nemtabrutinib
Chronic Lymphocytic Leukemia
Prevnar 13™
Pneumococcal Infections
Zoster Vaccine, Live (Zostavax™)
Shingles
DOR/ISL
HIV Infection
Rocuronium bromide (Org 9426)
Muscle Relaxation
Rocuronium 0.6 mg/kg intubating dose
Anesthesia
Rocuronium bolus maintenance
Anesthesia
V114
Pneumococcal Infections
sitagliptin phosphate
Type 2 Diabetes
Infliximab
Psoriasis
Ertugliflozin 15 mg
Type 2 Diabetes Mellitus
Metformin IR
Type 2 Diabetes Mellitus
Zoster Vaccine Live
Herpes Zoster
ER niacin/laropiprant
Diabetes Mellitus Type 2
Grazoprevir + Elbasvir
Hepatitis C Infection
Cetuximab + concomitant boost radiotherapy
Squamous Cell Carcinoma of the Head and Neck
L50/H12.5/A5
Hypertension
MK0826, /Duration of Treatment : 8 Weeks
Complicated Intra-Abdominal Infections
bortezomib
Multiple Myeloma
sugammadex
Neuromuscular Blockade
Tedizolid Phophate
Skin Diseases, Infectious
MK0507A, dorzolamide hydrochloride (+) timolol maleate
Glaucoma
MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks
Osteoporosis
raltegravir potassium
HIV Infections
rotavirus vaccine, live, oral, pentavalent
Rotavirus Infections
Grazoprevir/Elbasvir
Hepatitis C
Temozolomide
Glioblastoma
Cisplatin
Gastric Neoplasms
laropiprant/niacin (MK0524A)
Hypercholesterolemia
Sitagliptin
Type 2 Diabetes Mellitus
9vHPV vaccine
Papillomavirus Infections
Gonal-f®
Assisted Reproductive Techniques
Ibrutinib
Chronic Lymphocytic Leukemia
COL-1620
Luteal Hormone Supplementation in In-vitro Fertilization
V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine
Diphtheria
V501
Human
losartan potassium (+) hydrochlorothiazide
Hypertension
Opevesostat
Prostate Cancer Metastatic
Sotatercept
Pulmonary Arterial Hypertension
Bezlotoxumab
Clostridium Difficile Infection
PCV20
Pneumococcal Infection
Ertugliflozin
Type 2 Diabetes Mellitus
Peginterferon alfa-2b
Carcinoma, Hepatocellular
Ipragliflozin
Type 2 Diabetes Mellitus
Rocuronium bromide
Anesthesia
Pemetrexed
Carcinoma, Nonsquamous Non-small-cell Lung
IMI/REL
Suspected or Documented Gram-negative Bacterial Infection
MK0966, rofecoxib
Postoperative Pain
Posaconazole oral suspension
Mycoses
Follitropin alfa liquid formulation
Infertility
Micronised Progesterone
Infertility
Imipenem+Cilastatin/Relebactam
Complicated Intra-abdominal Infection
zoster vaccine live (ZOSTAVAX™)
Herpes Zoster
Doravirine
HIV-1
Telcagepant
Migraine
Lenvatinib
Non-small Cell Lung Cancer
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Human Papillomavirus Infection
V116
Pneumococcal Infection
Omarigliptin
Type 2 Diabetes Mellitus
MR Prednisone
Rheumatoid Arthritis
Pembrolizumab 200 mg
Non-Small-Cell Lung Carcinoma
Enfortumab vedotin (EV)
Bladder Cancer
Cetuximab
Gastric Cancer
Combination of (a) pegylated interferon alfa-2b and (b) rebetol
Liver Transplantation
Gefapixant 45 mg twice daily (BID)
Chronic Cough
Gefapixant
Chronic Cough
Indinavir sulfate
HIV Infections
Ridaforolimus
Sarcoma
V503
Papillomavirus Infections
Pembrolizumab/Vibostolimab Co-Formulation
Small Cell Lung Carcinoma
Prevnar 13®
Streptococcus Pneumoniae Infection
Saizen®
Fibromyalgia
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Measles
mFOLFOX6
Colorectal Carcinoma
Sitagliptin (MK0431)
Diabetes Mellitus, Type II
Cisplatin 100 mg/m^2
Head and Neck Neoplasms
Efavirenz
HIV Infections
Enlicitide Decanoate
Hypercholesterolemia
Odanacatib
Osteoporosis Postmenopausal
pegylated interferon alpha-2b
Hepatitis B, Chronic
V419
Bacterial Infections
Suvorexant
Insomnia
Rocuronium
Anesthesia, General
Gemcitabine
Biliary Tract Carcinoma
vaniprevir
Hepatitis C, Chronic
VARIVAX® PE34 Process
Varicella
Belzutifan
Renal Cell Carcinoma
Vorapaxar 2.5 mg
Cerebral Infarction
Rocurium
Anesthesia, General
Capecitabine
Advanced/Metastatic Gastroesophageal Adenocarcinoma
100 mg clindamycin /800 mg ketoconazole vaginal ovule
Vaginosis, Bacterial
QIV
Pneumonia, Pneumococcal
Acetaminophen/Paracetamol
Migraine Disorders
Ipilimumab
Melanoma
taranabant
Smoking
Nab-paclitaxel
Non-small Cell Lung Cancer
V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
Measles
V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years
Cervical Cancer
Enfortumab Vedotin
Urinary Bladder Cancer, Muscle-invasive
Cladribine Low Dose
Generalized Myasthenia Gravis
Metformin
Diabetes Mellitus
Colistimethate sodium (CMS)
Bacterial Infections
Acarbose
Type 2 Diabetes Mellitus
Fluorouracil (5-FU)
Urinary Bladder Neoplasms
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
HPV Infections
2XP HEPTAVAX™-II SC
Hepatitis B
Abiraterone acetate
Prostatic Neoplasms
DOR
HIV-1 Infection
denufosol tetrasodium (INS37217) Inhalation Solution
Cystic Fibrosis
succinylcholine
Neuromuscular Blockade
MK-1084
Colon Adenocarcinoma
peg-IFN
Hepatitis C, Chronic
MK1903
Dyslipidemia
Ulevostinag
Head and Neck Squamous Cell Carcinoma (HNSCC)
MK-5684
Malignant Neoplasm
denufosol tetrasodium (INS37217)
Cystic Fibrosis
OPT-80
Diarrhea
val-mCyd
Chronic Hepatitis C
Ertugliflozin 1 mg
Diabetes Mellitus, Type 2
MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks
Flushing
M5049 low dose
Systemic Lupus Erythematosus
Dalotuzumab
Carcinoma, Non-small-cell Lung
MK-8777
Depression
Everolimus
Metastatic Breast Cancer
Patritumab Deruxtecan
Malignant Neoplasm
ARQ 197
Pancreatic Neoplasms
ridaforolimus (MK8669)
Prostate Cancer
ARQ 501 in combination with gemcitabine
Pancreatic Cancer
ARQ 501
Cancer
Robatumumab
Colorectal Cancer
ADL5945 0.1 mg
Opioid Induced Constipation
MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks
Diabetes Mellitus, Type II
Donepezil
Alzheimer's Disease
M5717 330 mg
Acute Malaria
Pegylated Interferon Alfa
Chronic Hepatitis C
KW-3902IV
Heart Failure, Congestive
Favezelimab
Advanced Non-Small Cell Lung Cancer
tildrakizumab
Psoriasis
SCH 900538
Seasonal Allergic Rhinitis
Vibostolimab
Melanoma
MK0493
Obesity
MK0812 / Duration of Treatment: 12 Weeks
Arthritis, Rheumatoid
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
B-cell Lymphoma
EBR/GZR FDC Tablet
HCV Infection
SCH 56592
Onychomycosis
INS37217 Nasal Spray
Perennial Allergic Rhinitis
MK0916
Diabetes Mellitus, Type 2
MK0777
Generalized Anxiety Disorder
MK0524A, /Duration of Treatment : 8 Weeks
Flushing
Gefapixant 100 mg
Refractory Chronic Cough
Cabazitaxel
Prostatic Neoplasms, Castration-Resistant
Uprifosbuvir
Hepatitis C
L-dopa
Parkinson Disease
MK0364
Obesity
Pneumococcal Conjugate Vaccine (V114)
Pneumococcal Infections
Rolapitant Dose 1
Postoperative Nausea and Vomiting
Single low dose cyclophosphamide
Carcinoma, Non-Small-Cell Lung
V114 Aluminum-adjuvanted
Pneumococcal Infections
medroxyprogesterone acetate tablets OR megestrol acetate
Endometrial Cancer
Vibostolimab/Pembrolizumab
Carcinoma, Renal Cell
MK-8189
Schizophrenia, Acute Episode
MK-3120
Urothelial Carcinoma
MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks
Type 2 Diabetes Mellitus
Vicriviroc 30 mg
HIV Infections
Navarixin
Solid Tumors
Daptomycin for Injection
Bacteremia
valopicitabine
Chronic Hepatitis C
MK0677
Alzheimer's Disease
UFOX + Cetuximab
Previously Untreated Metastatic Colorectal Cancer
Recombinant human growth hormone (r-hGH)
Hypochondroplasia
Ritonavir
HIV Infections
MK0359
Pulmonary Disease, Chronic Obstructive
Grazoprevir/Elbasvir FDC
Hepatitis C
Sofosbuvir
Hepatitis C
ARQ 197 plus erlotinib
Metastatic Non-Small Cell Lung Cancer
Raludotatug Deruxtecan (R-DXd)
Gastrointestinal Cancer
Stavudine
HIV Infections
Tepotinib
Non-small Cell Lung Cancer
MK0524
Seasonal Allergies
MK-3795
VHL Gene Mutation
Efprezimod alfa
Graft Versus Host Disease
boceprevir (SCH 503034)
Chronic Hepatitis C
MK0991, caspofungin acetate/Duration of Treatment: variable
Candidiasis
Posaconazole IV 6 mg/kg
Invasive Fungal Infection
Boserolimab
Small Cell Lung Cancer
V114 Lot 1
Pneumococcal Infections
peginterferon alfa 2b
Hepatitis C, Chronic
TRUVADA®
HIV Infections
2 NRTIs
Human Immunodeficiency Virus (HIV) Infection
luspatercept
B-Thalassemia
Tulisokibart
Hidradenitis Suppurativa
PegIFN-2b
HIV Infections
TR701 FA
Major Cutaneous Abscess
TS-1
Gastric Cancer
adavosertib
Ovarian Cancer
PegIntron (peginterferon alfa-2b)
Hepatitis C, Chronic
Relebactam 250 mg
Intra-abdominal Infections
Atorvastatin/niacin extended-release
Carotid Atherosclerosis
Antihistamine
Esophageal Squamous Cell Carcinoma
MK0249
Attention-Deficit/Hyperactivity Disorder (ADHD)
Rebif
Multiple Sclerosis
MK-5442
Osteoporosis
Oral testosterone undecanoate (Andriol)
Hypogonadism
Azithromycin ophthalmic solution, 1%
Blepharitis
Vorapaxar
Atherosclerosis
MK-8435 (Org 25935) 4-8 mg
Schizophrenia
Docetetaxel
Carcinoma, Non-Small-Cell Lung
Rescue
Type II Diabetes Mellitus
Ceftolozane/Tazobactam
Complicated Intra-Abdominal Infection
MK-0873
Rheumatoid Arthritis
Matuzumab
Esophageal Cancer
MK-6096
Migraine
Pembrolizumab/vibostolimab coformulation
Bladder Cancer
PR51 (3, 10)
Bacterial Infections; Virus Diseases
V504
Cervical Cancer
irinotecan hydrochloride
Metastatic Colorectal Cancer
Pertuzumab
Breast Neoplasms
epinastine 0.1%
Allergic Rhinitis
MK-0941
Type 2 Diabetes Mellitus
imipenem/cilastatin 500 mg
Urinary Tract Infections
Recombinant human follicle stimulating hormone (r-hFSH)
Infertility
MK0518
HIV Infections
Olaparib 400 mg
Metastatic Castration-Resistant Prostate Cancer
Ramucirumab
Gastroesophageal Junction
Vaniprevir 600 mg b.i.d.
Hepatitis C, Chronic
cetuximab, cisplatin
Breast Neoplasm
Interferon beta-1a
Alzheimer's Disease
ibuprofen
Migraine
V114 Medium Dose
Pneumococcal Infections
IDX719
Hepatitis C, Chronic
V181 High-Potency Level
Dengue Disease
Itraconazole
Chronic Hepatitis C
Prednisolone
Lymphoma, Large B-Cell, Diffuse
Biltricide (racemate praziquantel) oral tablets
Schistosomiasis
CXA-101/ tazobactam and metronidazole
Complicated Intra-abdominal Infection
Islatravir
HIV-1 Infection
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Infertility Implantation Failure
Preladenant
Parkinson Disease
Sacituzumab Tirumotecan (sac-TMT)
Gastroesophageal Junction
Dalantercept plus sorafenib
Advanced Adult Hepatocellular Carcinoma
Pegylated Interferon (peg-IFN)
Hepatitis C
Nelfinavir mesylate
HIV Infections
Risperidone
Schizophrenia
Doravirine, Tenofovir, Lamivudine - Blinded
HIV-1
MK2295
Pain, Postoperative
V940
Squamous Non-small Cell Lung Cancer
M5717 60 mg
Malaria Infection
R-DXD
Lung Neoplasm
Efinopegdutide
Metabolic Dysfunction-Associated Steatotic Liver Disease
Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20
Papillomavirus Infections
AR51 (12, 10)
Bacterial Infections; Virus Diseases
diphenhydramine
Carcinoma, Non-Small-Cell Lung
MK0429
Post-Menopausal Osteoporosis
Navarixin 10 mg
Psoriasis
Quavonlimab
Advanced Solid Tumors
Miransertib
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
MK8141
Hypertension
MK-1167
Alzheimer Disease
SCH 530348
Arterial Obstructive Diseases
MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks
HIV Infections
SCH 619734
Cough
MK-0893
Diabetes Mellitus, Type 2
Epinastine Nasal Spray
Seasonal Allergic Rhinitis
Clesrovimab
Respiratory Syncytial Viruses
Ruzasvir
Hepatitis C
MK0686
Pain, Postoperative
MK0822A
Vitamin D Deficiency
MK0633
Atherosclerosis
ZA
Breast Cancer
Gefitinib
Non-small Cell Lung Carcinoma
Avelumab
Squamous Non-Small Cell Lung Cancer
MK-4830
Carcinoma, Non-Small-Cell Lung
L-756423
HIV Infections
TR-701 200 mg
Skin Diseases, Infectious
timolol/dorzolamide combination
Glaucoma
MK-6213
Hypercholesterolemia
zoster vaccine live (Oka/Merck)
Shingles
vinblastine
Hodgkin Lymphoma
Raludotatug Deruxtecan
Ovarian Cancer Recurrent
Esmeron®
Neuromuscular Blockade
MK-1029 150 mg
Asthma
VigantOL oil plus interferon beta-1a (Rebif)
Relapsing-Remitting Multiple Sclerosis
r-hFSH
Infertility
Coformulation favezelimab/pembrolizumab
Esophageal Squamous Cell Carcinoma (ESCC)
NM283 plus Peg-IFNα-2a
Chronic Hepatitis C
Lonafarnib
Breast Cancer
Gefapixant 50 mg
Asthma
Sitagliptin 25 mg
Glucose Intolerance
Letermovir oral granules
Cytomegalovirus (CMV) Infection
MK-2060
End-Stage Renal Disease
IDX184
Chronic Hepatitis C Infection
Pleconaril
Asthma
Gocatamig
Small-Cell Lung Cancer
ADL5859 30 mg
Acute Pain
Fosaprepitant
Chemotherapy-induced Nausea and Vomiting
MK3207- 2.5 mg
Migraine
MK-1200
Advanced Solid Tumors
BCG
Urinary Bladder Neoplasms
teicoplanin
Osteomyelitis
Cilengitide 2000 mg once weekly
Squamous Cell Cancer
Gefapixant 45 mg
Chronic Cough
Farnesyl Protein Transferase Inhibitor
Leukemia
SCH 727965
Breast Neoplasms
Palbociclib
Renal Cell Carcinoma
ADL5859
Peripheral Neuropathy
MK2461
Neoplasm
V114-A
Pneumococcal Infections
IFN beta 1a 44 mcg TIW
Multiple Sclerosis
Pegylated Liposomal Doxorubicin
Breast Neoplasm
S-1
Gastric Cancer
MK0991, caspofungin acetate
Aspergillosis
SCH 486757
Cough
Tecemotide (L-BLP25)
Lung Neoplasms
measles, mumps, and rubella virus vaccine live
Measles
Vicriviroc maleate
HIV
Tepotinib 300 mg
Carcinoma, Hepatocellular
SCH 900271 15mg
Primary Hypercholesterolemia
Vecuronium
Anesthesia, General
Avastin
High-grade Serous Ovarian Carcinoma
AS900672-Enriched 50 microgram (mcg)
Infertility
MK633
Chronic Obstructive Pulmonary Disease (COPD)
Atacicept
Rheumatoid Arthritis
Cilengitide
Carcinoma, Non-Small-Cell Lung
Grazoprevir (GZR)
Hepatitis C Virus
Vibegron
Urinary Bladder, Overactive
Doxorubicin hydrochloride
Breast Neoplasms
ecallantide
Bloodloss
r-FSH
Ovarian Stimulation
Org 34517
Depression
Enclitide Chloride
Hypercholesterolemia
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
HIV-1 Infection
Pembrolizumab (neoadjuvant)
Lung Neoplasm Malignant
ADL5945 0.25 mg
Constipation
Coformulated favezelimab/pembrolizumab
Metastatic Urothelial Carcinoma
I-DXd
Esophageal Squamous Cell Carcinoma
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
MK0966; Rofecoxib / Duration of Treatment: 156 weeks | Phase 3 | Colorectal Adenoma | - |
V503 Vaccine | Phase 3 | Papillomavirus Infections | - |
Saizen® A | Phase 3 | Children Born With Serious Intra-uterine Growth Retardation | - |
Modified Process Hepatitis B Vaccine | Phase 3 | Hepatitis B | - |
MK0557 | Phase 3 | Obesity | - |
Pembrolizumab Formulated with Berahyaluronidase Alfa | Phase 3 | Metastatic Non-small Cell Lung Cancer | - |
Pneumovax™ 23 | Phase 3 | Pneumococcal Infections | - |
Posaconazole | Phase 3 | Mycoses | - |
Metformin - Rescue | Phase 3 | Diabetes Mellitus, Type 2 | - |
Infanrix® hexa | Phase 3 | Varicella | - |
IV Tulisokibart | Phase 3 | Crohn's Disease | - |
Daptomycin 4 mg/kg | Phase 3 | Staphylococcal Infection | - |
Gonalef® (Follitropin alfa) | Phase 3 | Infertility | - |
Fluconazole | Phase 3 | Leukopenia | - |
MK0826, ertapenem sodium / Duration of Treatment - 24 weeks | Phase 3 | Foot Infections in Diabetic Patients | - |
Naproxen | Phase 3 | Endometriosis-related Pain | - |
fidaxomicin | Phase 3 | Clostridium Difficile-Associated Diarrhea (CDAD) | - |
Zoster Vaccine, Live | Phase 3 | Herpes Zoster | - |
losartan potassium | Phase 3 | Hypertension | - |
anacetrapib | Phase 3 | Coronary Heart Disease (CHD) | - |
dorzolamide hydrochloride (+) timolol maleate | Phase 3 | Glaucoma | - |
rofecoxib | Phase 3 | Prostate Cancer | - |
ProQuad® | Phase 3 | Measles | - |
RotaTeq™, rotavirus vaccine, live, oral, pentavalent | Phase 3 | Rotavirus Infections | - |
Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) | Phase 3 | Papillomavirus Infections | - |
Infliximab + methotrexate (IFX + MTX) | Phase 3 | Arthritis, Psoriatic | - |
Rebif New Formulation + prophylactic Ibuprofen | Phase 3 | Relapsing Multiple Sclerosis | - |
PPSV23 | Phase 3 | Pneumococcal Disease | - |
Boceprevir | Phase 3 | Chronic Hepatitis C Genotype 1 | - |
Esmirtazapine | Phase 3 | Insomnia | - |
hydrochlorothiazide (HCTZ) | Phase 3 | Hypertension | - |
PNEUMOVAX™23 | Phase 3 | Pneumococcal Infections | - |
Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Phase 3 | Head and Neck Cancer | - |
Ertapenem sodium | Phase 3 | Infection; Diabetic Foot | - |
MK0826, ertapenem sodium / Duration of Treatment: 14 Days | Phase 3 | Infection | - |
Prednisone | Phase 3 | Prostatic Neoplasms | - |
pneumococcal 23v polysaccharide vaccine | Phase 3 | Pneumococcal Infection | - |
niacin (+) laropiprant (+) simvastatin | Phase 3 | Primary Hypercholesterolemia | - |
Modified Process Hepatitis B Vaccine (Experimental) | Phase 3 | Hepatitis B | - |
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) | Phase 3 | Papillomavirus Infections | - |
V212 | Phase 3 | Herpes Zoster | - |
Dexamethasone 4 mg | Phase 3 | Non-Small-Cell Lung Carcinoma | - |
Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®) | Phase 3 | Hepatitis C, Chronic | - |
Open-label Metformin | Phase 3 | Type 2 Diabetes | - |
Olaparib | Phase 3 | Ovarian Cancer | - |
Pembrolizumab 400 mg | Phase 3 | Small Cell Lung Cancer | - |
RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent | Phase 3 | Vomiting | - |
docetaxel | Phase 3 | Endometrial Neoplasms | - |
Rescue Medications | Phase 3 | Cervical Cancer | - |
MTX | Phase 3 | Arthritis, Rheumatoid | - |
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Phase 3 | Cervical Cancer | - |
V920 Consistency Lot A | Phase 3 | Prevention of Ebola Infection | - |
Peginterferon alfa-2a | Phase 3 | Hepatitis C, Chronic | - |
Letermovir | Phase 3 | Cytomegalovirus Infection | - |
Sacituzumab tirumotecan | Phase 3 | Colorectal Cancer | - |
V232 Modified Process Hepatitis B Vaccine: Lot A | Phase 3 | Hepatitis B Infection | - |
PCV13 | Phase 3 | Pneumococcal Infections | - |
Varicella Virus Vaccine Live (2007 Process) (Oka/Merck) | Phase 3 | Varicella | - |
Ribavirin | Phase 3 | Hepatitis C | - |
Anacetrapib 100 mg | Phase 3 | Hypercholesterolemia | - |
Gardasil™ | Phase 3 | Papillomavirus Infections | - |
Tobramycin | Phase 3 | Bacterial Conjunctivitis | - |
Pegylated interferon alfa-2b | Phase 3 | Hepatitis C | - |
Basal Insulin | Phase 3 | Type 2 Diabetes Mellitus | - |
0.9% sodium chloride (NaCl) | Phase 3 | Anesthesia | - |
sac-TMT | Phase 3 | Non-small Cell Lung Cancer | - |
Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A) | Phase 3 | Chronic Hepatitis C | - |
Org 50081 | Phase 3 | Insomnia | - |
HBVAXPRO™ | Phase 3 | Hepatitis B | - |
VARIVAX™ | Phase 3 | Varicella | - |
SC Tulisokibart | Phase 3 | Ulcerative Colitis | - |
Insulin | Phase 3 | Type 2 Diabetes Mellitus | - |
Vericiguat | Phase 3 | Heart Failure | - |
DAPTACEL™ | Phase 3 | Bacterial Infections | - |
etoposide | Phase 3 | Carcinoma, Non-Small-Cell Lung | - |
IMI/REL FDC | Phase 3 | Hospital-Acquired Bacterial Pneumonia | - |
Vicriviroc | Phase 3 | HIV Infections | - |
Molnupiravir | Phase 3 | Coronavirus Disease (COVID-19) | - |
losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E) | Phase 3 | Hypertension | - |
ertapenem sodium (MK0826) | Phase 3 | Urinary Tract Infection | - |
Pegylated liposomal doxorubicin (SCH 200746) | Phase 3 | Breast Cancer | - |
Enzalutamide | Phase 3 | Metastatic Hormone-Sensitive Prostate Cancer | - |
peginterferon alfa-2b (SCH 54031) | Phase 3 | Chronic Hepatitis C | - |
Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin | Phase 3 | Hepatitis C, Chronic | - |
Pembrolizumab SC | Phase 3 | Non-Small Cell Lung Cancer | - |
ISL | Phase 3 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | - |
TR-701 FA | Phase 3 | Skin and Subcutaneous Tissue Bacterial Infections | - |
Neostigmine | Phase 3 | Anesthesia | - |
5-Fluorouracil | Phase 3 | Uterine Cervical Neoplasms | - |
CB-183,315 | Phase 3 | Clostridium Difficile Infection | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - |
ceftriaxone sodium | Phase 3 | Infection | - |
PCV15 | Phase 3 | Pneumonia, Pneumococcal | - |
eribulin | Phase 3 | Metastatic Triple Negative Breast Cancer | - |
Sitagliptin 50 mg | Phase 3 | Type 2 Diabetes Mellitus | - |
Preservative-Free Tafluprost or vehicle | Phase 3 | Glaucoma | - |
Preladenant 2 mg tablet | Phase 3 | Parkinson Disease | - |
Recombinant human luteinizing hormone (r-hLH) | Phase 3 | Hypogonadism | - |
Experimental: V503 | Phase 3 | Cervical Cancer | - |
Peginterferon alfa-2b (PegIntron, SCH 54031) | Phase 3 | Hepatitis D, Chronic | - |
RNF | Phase 3 | Multiple Sclerosis | - |
H1 receptor antagonist | Phase 3 | Ovarian Cancer | - |
V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years | Phase 3 | Cervical Cancer | - |
Telcagepant potassium 150 mg | Phase 3 | Migraine | - |
Hepatitis A Vaccine, Purified Inactivated (VAQTA™) | Phase 3 | Hepatitis A Virus Infection | - |
Vancomycin | Phase 3 | Clostridium Difficile Infection | - |
Ondansetron | Phase 3 | Chemotherapy-Induced Nausea and Vomiting (CINV) | - |
Anagrelide | Phase 3 | Essential Thrombocythemia | - |
ULO | Phase 3 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | - |
Telcagepant 140 mg | Phase 3 | Migraines | - |
Telcagepant 300 mg soft gel capsules | Phase 3 | Migraine | - |
Leucovorin | Phase 3 | Gastric Cancer | - |
Rotarix™ | Phase 3 | Pneumococcal Infections | - |
MK-3415 | Phase 3 | Clostridium Difficile Infection | - |
Leucovorin/ levoleucovorin | Phase 3 | Metastatic Colorectal Cancer | - |
epinastine nasal spray, low concentration, low dose volume | Phase 3 | Seasonal Allergic Rhinitis | - |
Letermovir tablet | Phase 3 | Cytomegalovirus Infection | - |
peginterferon alfa-2b (PEG2b) (SCH 54031) | Phase 3 | Hepatitis C, Chronic | - |
Prulifloxacin | Phase 3 | Acute Gastroenteritis in Adult Travelers | - |
Efalizumab | Phase 3 | Moderate to Severe Psoriasis | - |
Suvorexant High Dose (HD) | Phase 3 | Primary Insomnia | - |
FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Phase 3 | Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer | - |
Sacituzumab Govitecan | Phase 3 | Carcinoma, Non-Small-Cell Lung | - |
Valganciclovir | Phase 3 | CMV Disease | - |
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) | Phase 3 | Intra-abdominal Infection | - |
Uridine 5'-Triphosphate (UTP) Solution for Inhalation | Phase 3 | Lung Cancer | - |
Glycopyrrolate | Phase 3 | Surgical Procedures, Elective | - |
Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) | Phase 3 | Rotavirus | - |
MK0524A, /Duration of Treatment : 4 Weeks | Phase 3 | Flushing | - |
Rebif® New Formulation (IFN-beta-1a, RNF) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - |
ART | Phase 3 | HIV-1 Infection | - |
Sitagliptin plus metformin | Phase 3 | Type 2 Diabetes Mellitus | - |
Linezolid | Phase 3 | Pneumonia | - |
liposomal doxorubicin | Phase 3 | Breast Neoplasms | - |
diquafosol tetrasodium (INS365) ophthalmic solution | Phase 3 | Dry Eye Disease | - |
REBETOL (ribavirin; SCH 18908) | Phase 3 | Hepatitis C, Chronic | - |
AzaSite | Phase 3 | Bacterial Conjunctivitis | - |
rosiglitazone | Phase 3 | Type 2 Diabetes Mellitus | - |
VARIVAX™ New Seed Process | Phase 3 | Varicella | - |
levoleucovorin | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) | - |
Cetuximab plus Platinum-based Doublet Chemotherapy | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) | - |
ribavirin (SCH 18908) | Phase 3 | Hepatitis C, Chronic | - |
MK-0524B | Phase 3 | Primary Hypercholesterolemia | - |
Cyclophosphamide | Phase 3 | Diffuse Large B-Cell Lymphoma | - |
lovastatin | Phase 3 | Atherosclerosis | - |
MMRV (AMP) | Phase 3 | Measles | - |
Folinic Acid | Phase 3 | Metastatic Colorectal Cancer | - |
Lamivudine | Phase 3 | HIV Infections | - |
RotaTeq™ experimental formulation | Phase 3 | Rotavirus Gastroenteritis | - |
Ifinatamab Deruxtecan | Phase 3 | Castration-Resistant Prostatic Cancer | - |
Insulin Glargine | Phase 3 | Type 2 Diabetes Mellitus | - |
Bomedemstat | Phase 3 | Thrombocythemia, Essential | - |
Sulfonylurea | Phase 3 | Type 2 Diabetes Mellitus | - |
Pembrolizumab (MK-3475) | Phase 3 | Merkel Cell Carcinoma | - |
Hydroxyurea | Phase 3 | Essential Thrombocythemia | - |
Zidovudine | Phase 3 | HIV Infections | - |
Glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - |
MK-0518 | Phase 3 | HIV Infections | - |
Grazoprevir 100mg / Elbasvir 50 mg FDC | Phase 3 | Chronic Hepatitis C Virus | - |
Kuvan® | Phase 3 | Phenylketonuria | - |
Pioglitazone hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - |
Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets | Phase 3 | Chronic Hepatitis C | - |
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ | Phase 3 | Herpes Zoster | - |
Ertugliflozin 10 mg | Phase 3 | Type 2 Diabetes Mellitus | - |
Peg-interferon alfa-2b | Phase 3 | Hepatitis C, Chronic | - |
Rotateq™ | Phase 3 | Rotavirus Infections | - |
MK-8527 | Phase 3 | Human Immunodeficiency Virus (HIV) | - |
PCV15 - Part B | Phase 3 | Pneumococcal Disease | - |
Zilovertamab vedotin | Phase 3 | B-cell Acute Lymphoblastic Leukemia | - |
Doravirine, Tenofovir, Lamivudine | Phase 3 | HIV-1 Infection | - |
Pembrolizumab/Quavonlimab | Phase 3 | Colorectal Cancer | - |
MK-5172A | Phase 3 | Chronic Hepatitis C | - |
PegIntron (peginterferon alfa-2b; SCH 54031) | Phase 3 | Hepatitis | - |
Grazoprevir | Phase 3 | Chronic Hepatitis C (CHC) | - |
PEG-Intron | Phase 3 | Hepatitis C | - |
Granulocyte Colony-Stimulating Factor (G-CSF) | Phase 3 | DLBCL | - |
Emtricitabine/tenofovir disoproxil (FTC/TDF) | Phase 3 | Human Immunodeficiency Virus (HIV) | - |
peg-Interferon alfa-2a | Phase 3 | Hepatitis C, Chronic | - |
Zoster Vaccine, Live (AMP) | Phase 3 | Herpes Zoster | - |
Cisplatin/Carboplatin | Phase 3 | Carcinoma, Squamous Cell of Head and Neck | - |
Fosaprepitant dimeglumine | Phase 3 | Chemotherapy-Induced Nausea and Vomiting (CINV) | - |
Aprepitant 125 mg | Phase 3 | Chemotherapy Induced Nausea and Vomiting | - |
Human Papillomavirus (HPV) 16 Monovalent | Phase 3 | Cervical Cancer | - |
Atropine | Phase 3 | Anesthesia, General | - |
Glycemic Rescue 1 | Phase 3 | Diabetes Mellitus | - |
Axitinib | Phase 3 | Renal Cell Carcinoma | - |
Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d. | Phase 3 | Type 2 Diabetes Mellitus | - |
Androgen Deprivation Therapy (ADT) | Phase 3 | Metastatic Hormone-Sensitive Prostate Cancer | - |
ZOSTAVAX | Phase 3 | Herpes Zoster | - |
Dacarbazine | Phase 3 | Classical Hodgkin Lymphoma | - |
Cisplatin (as radiosensitizer) | Phase 3 | Endometrial Neoplasms | - |
Boceprevir (BOC) | Phase 3 | Chronic Hepatitis C | - |
Intismeran autogene | Phase 3 | Bladder Cancer | - |
MK0869, aprepitant | Phase 3 | Postoperative Nausea and Vomiting | - |
Cabozantinib | Phase 3 | Renal Cell Carcinoma (RCC) | - |
Voriconazole | Phase 3 | Aspergillosis | - |
Short ragweed pollen allergen extract | Phase 3 | Rhinitis, Allergic, Seasonal | - |
MK0803, lovastatin | Phase 3 | Hypercholesterolemia | - |
Trifluridine-Tipiracil | Phase 3 | Gastroesophageal Cancer | - |
Rescue medication | Phase 3 | Non-Muscle Invasive Bladder Cancer | - |
Tisotumab Vedotin | Phase 3 | Cervical Cancer | - |
niacin (+) laropiprant | Phase 3 | Hypercholesterolemia | - |
TAS-102 (trifluridine and tipiracil) | Phase 3 | Colorectal Neoplasms | - |
Diquafosol tetrasodium ophthalmic solution, 2% | Phase 3 | Dry Eye Disease | - |
favezelimab/pembrolizumab | Phase 3 | Hodgkin Lymphoma | - |
Golimumab | Phase 3 | Spondylitis, Ankylosing | - |
TAS-102 | Phase 3 | Colorectal Cancer | - |
Infliximab + methotrexate (MTX) | Phase 3 | Arthritis, Rheumatoid | - |
Gefapixant 15 mg BID | Phase 3 | Chronic Cough | - |
Standard of Care (SOC) | Phase 3 | Solid Tumors | - |
Enalapril | Phase 3 | Hypertension | - |
Tedizolid phosphate | Phase 3 | Acute Bacterial Skin and Skin Structure Infections | - |
SC golimumab | Phase 3 | Arthritis, Rheumatoid | - |
Sitagliptin 100 mg | Phase 3 | Type 2 Diabetes Mellitus | - |
Voglibose | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - |
ER-niacin | Phase 3 | Primary Hypercholesterolaemia | - |
MK-1293 | Phase 3 | Type 1 Diabetes Mellitus | - |
CXA-201 and metronidazole | Phase 3 | Complicated Intra-abdominal Infection | - |
PAR-101/OPT-80 | Phase 3 | Clostridium Infections | - |
ZOSTAVAX™ | Phase 3 | Herpes Zoster | - |
cetuximab + cisplatin + vinorelbine | Phase 3 | Non Small Cell Lung Cancer (NSCLC) | - |
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - |
ER niacin (+) laropiprant (ERN/LRPT) | Phase 3 | Dyslipidemia | - |
Vancomycin (or equivalent) | Phase 3 | Acute Hematogenous Osteomyelitis | - |
Elbasvir | Phase 3 | Hepatitis C | - |
Zanzalintinib | Phase 3 | Renal Cell Carcinoma | - |
methotrexate | Phase 3 | Psoriasis | - |
5-FU | Phase 3 | Metastatic Esophageal Squamous Cell Carcinoma | - |
Vorinostat | Phase 3 | Mesothelioma | - |
Oxaliplatin | Phase 3 | Colorectal Neoplasms | - |
rolofylline | Phase 3 | Heart Failure, Congestive | - |
Gardasil | Phase 3 | Papillomavirus Infections | - |
Cetrorelix acetate | Phase 3 | Polycystic Ovarian Syndrome | - |
MK0966 / Duration of Treatment: 1 Days | Phase 3 | Pain, Postoperative Arthroscopy | - |
RotaTeq (V260) | Phase 3 | Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9 | - |
Aprepitant | Phase 3 | Post-operative Nausea | - |
Frespaciguat | Phase 3 | Pulmonary Hypertension | - |
Pembrolizumab/Vibostolimab | Phase 3 | Lung Neoplasms | - |
caspofungin acetate | Phase 3 | Fungal Infection | - |
MK0826, ertapenem sodium | Phase 3 | Infections | - |
Pembrolizumab (+) Berahyaluronidase alfa | Phase 3 | Lung Cancer | - |
Paclitaxel | Phase 3 | Metastatic Non-Small Cell Lung Cancer | - |
MK-6072 | Phase 3 | Clostridium Difficile Infection | - |
Gliclazide | Phase 3 | Type 2 Diabetes Mellitus | - |
MK-0524A | Phase 3 | Hypercholesteremia | - |
Supportive care measures | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - |
ZOSTAVAX™ (concomitant) | Phase 3 | Herpes Zoster | - |
Doxorubicin | Phase 3 | Breast Neoplasms | - |
MK0974 50 mg | Phase 3 | Migraine | - |
Vitamin D3 | Phase 3 | Osteoporosis | - |
MK0869, aprepitant / Duration of Treatment: 3 days | Phase 3 | Nausea | - |
neostigmine and glycopyrrolate or atropine | Phase 3 | Neuromuscular Blockade | - |
INS365 Ophthalmic Solution | Phase 3 | Keratoconjunctivitis Sicca | - |
Glipizide | Phase 3 | Diabetes Mellitus, Type 2 | - |
Dexamethasone | Phase 3 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | - |
M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® | Phase 3 | Measles | - |
regorafenib | Phase 3 | Colorectal Cancer | - |
sitagliptin phosphate (+) metformin hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - |
V110, pneumococcal vaccine polyvalent | Phase 3 | Healthy | - |
Reformulated Raltegravir | Phase 3 | HIV Infection | - |
Background PAH Therapy | Phase 3 | Pulmonary Arterial Hypertension | - |
BIC/FTC/TAF | Phase 3 | HIV-1 Infection | - |
MK0991, caspofungin acetate / Duration of Treatment: | Phase 3 | Fungal Infection | - |
daptomycin | Phase 3 | Pneumonia, Bacterial | - |
Ertugliflozin 5 mg | Phase 3 | Type 2 Diabetes Mellitus | - |
Carboplatin | Phase 3 | Carcinoma, Squamous Cell, Non-small-cell Lung | - |
alvimopan | Phase 3 | Ileus | - |
pembrolizumab | Phase 3 | Non-small Cell Lung Cancer | - |
Nemtabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - |
Prevnar 13™ | Phase 3 | Pneumococcal Infections | - |
Zoster Vaccine, Live (Zostavax™) | Phase 3 | Shingles | - |
DOR/ISL | Phase 3 | HIV Infection | - |
Rocuronium bromide (Org 9426) | Phase 3 | Muscle Relaxation | - |
Rocuronium 0.6 mg/kg intubating dose | Phase 3 | Anesthesia | - |
Rocuronium bolus maintenance | Phase 3 | Anesthesia | - |
V114 | Phase 3 | Pneumococcal Infections | - |
sitagliptin phosphate | Phase 3 | Type 2 Diabetes | - |
Infliximab | Phase 3 | Psoriasis | - |
Ertugliflozin 15 mg | Phase 3 | Type 2 Diabetes Mellitus | - |
Metformin IR | Phase 3 | Type 2 Diabetes Mellitus | - |
Zoster Vaccine Live | Phase 3 | Herpes Zoster | - |
ER niacin/laropiprant | Phase 3 | Diabetes Mellitus Type 2 | - |
Grazoprevir + Elbasvir | Phase 3 | Hepatitis C Infection | - |
Cetuximab + concomitant boost radiotherapy | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - |
L50/H12.5/A5 | Phase 3 | Hypertension | - |
MK0826, /Duration of Treatment : 8 Weeks | Phase 3 | Complicated Intra-Abdominal Infections | - |
bortezomib | Phase 3 | Multiple Myeloma | - |
sugammadex | Phase 3 | Neuromuscular Blockade | - |
Tedizolid Phophate | Phase 3 | Skin Diseases, Infectious | - |
MK0507A, dorzolamide hydrochloride (+) timolol maleate | Phase 3 | Glaucoma | - |
MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks | Phase 3 | Osteoporosis | - |
raltegravir potassium | Phase 3 | HIV Infections | - |
rotavirus vaccine, live, oral, pentavalent | Phase 3 | Rotavirus Infections | - |
Grazoprevir/Elbasvir | Phase 3 | Hepatitis C | - |
Temozolomide | Phase 3 | Glioblastoma | - |
Cisplatin | Phase 3 | Gastric Neoplasms | - |
laropiprant/niacin (MK0524A) | Phase 3 | Hypercholesterolemia | - |
Sitagliptin | Phase 3 | Type 2 Diabetes Mellitus | - |
9vHPV vaccine | Phase 3 | Papillomavirus Infections | - |
Gonal-f® | Phase 3 | Assisted Reproductive Techniques | - |
Ibrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - |
COL-1620 | Phase 3 | Luteal Hormone Supplementation in In-vitro Fertilization | - |
V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine | Phase 3 | Diphtheria | - |
V501 | Phase 3 | Human | - |
losartan potassium (+) hydrochlorothiazide | Phase 3 | Hypertension | - |
Opevesostat | Phase 3 | Prostate Cancer Metastatic | - |
Sotatercept | Phase 3 | Pulmonary Arterial Hypertension | - |
Bezlotoxumab | Phase 3 | Clostridium Difficile Infection | - |
PCV20 | Phase 3 | Pneumococcal Infection | - |
Ertugliflozin | Phase 3 | Type 2 Diabetes Mellitus | - |
Peginterferon alfa-2b | Phase 3 | Carcinoma, Hepatocellular | - |
Ipragliflozin | Phase 3 | Type 2 Diabetes Mellitus | - |
Rocuronium bromide | Phase 3 | Anesthesia | - |
Pemetrexed | Phase 3 | Carcinoma, Nonsquamous Non-small-cell Lung | - |
IMI/REL | Phase 3 | Suspected or Documented Gram-negative Bacterial Infection | - |
MK0966, rofecoxib | Phase 3 | Postoperative Pain | - |
Posaconazole oral suspension | Phase 3 | Mycoses | - |
Follitropin alfa liquid formulation | Phase 3 | Infertility | - |
Micronised Progesterone | Phase 3 | Infertility | - |
Imipenem+Cilastatin/Relebactam | Phase 3 | Complicated Intra-abdominal Infection | - |
zoster vaccine live (ZOSTAVAX™) | Phase 3 | Herpes Zoster | - |
Doravirine | Phase 3 | HIV-1 | - |
Telcagepant | Phase 3 | Migraine | - |
Lenvatinib | Phase 3 | Non-small Cell Lung Cancer | - |
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Phase 3 | Human Papillomavirus Infection | - |
V116 | Phase 3 | Pneumococcal Infection | - |
Omarigliptin | Phase 3 | Type 2 Diabetes Mellitus | - |
MR Prednisone | Phase 3 | Rheumatoid Arthritis | - |
Pembrolizumab 200 mg | Phase 3 | Non-Small-Cell Lung Carcinoma | - |
Enfortumab vedotin (EV) | Phase 3 | Bladder Cancer | - |
Cetuximab | Phase 3 | Gastric Cancer | - |
Combination of (a) pegylated interferon alfa-2b and (b) rebetol | Phase 3 | Liver Transplantation | - |
Gefapixant 45 mg twice daily (BID) | Phase 3 | Chronic Cough | - |
Gefapixant | Phase 3 | Chronic Cough | - |
Indinavir sulfate | Phase 3 | HIV Infections | - |
Ridaforolimus | Phase 3 | Sarcoma | - |
V503 | Phase 3 | Papillomavirus Infections | - |
Pembrolizumab/Vibostolimab Co-Formulation | Phase 3 | Small Cell Lung Carcinoma | - |
Prevnar 13® | Phase 3 | Streptococcus Pneumoniae Infection | - |
Saizen® | Phase 3 | Fibromyalgia | - |
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live | Phase 3 | Measles | - |
mFOLFOX6 | Phase 3 | Colorectal Carcinoma | - |
Sitagliptin (MK0431) | Phase 3 | Diabetes Mellitus, Type II | - |
Cisplatin 100 mg/m^2 | Phase 3 | Head and Neck Neoplasms | - |
Efavirenz | Phase 3 | HIV Infections | - |
Enlicitide Decanoate | Phase 3 | Hypercholesterolemia | - |
Odanacatib | Phase 3 | Osteoporosis Postmenopausal | - |
pegylated interferon alpha-2b | Phase 3 | Hepatitis B, Chronic | - |
V419 | Phase 3 | Bacterial Infections | - |
Suvorexant | Phase 3 | Insomnia | - |
Rocuronium | Phase 3 | Anesthesia, General | - |
Gemcitabine | Phase 3 | Biliary Tract Carcinoma | - |
vaniprevir | Phase 3 | Hepatitis C, Chronic | - |
VARIVAX® PE34 Process | Phase 3 | Varicella | - |
Belzutifan | Phase 3 | Renal Cell Carcinoma | - |
Vorapaxar 2.5 mg | Phase 3 | Cerebral Infarction | - |
Rocurium | Phase 3 | Anesthesia, General | - |
Capecitabine | Phase 3 | Advanced/Metastatic Gastroesophageal Adenocarcinoma | - |
100 mg clindamycin /800 mg ketoconazole vaginal ovule | Phase 3 | Vaginosis, Bacterial | - |
QIV | Phase 3 | Pneumonia, Pneumococcal | - |
Acetaminophen/Paracetamol | Phase 3 | Migraine Disorders | - |
Ipilimumab | Phase 3 | Melanoma | - |
taranabant | Phase 3 | Smoking | - |
Nab-paclitaxel | Phase 3 | Non-small Cell Lung Cancer | - |
V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks | Phase 3 | Measles | - |
V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years | Phase 3 | Cervical Cancer | - |
Enfortumab Vedotin | Phase 3 | Urinary Bladder Cancer, Muscle-invasive | - |
Cladribine Low Dose | Phase 3 | Generalized Myasthenia Gravis | - |
Metformin | Phase 3 | Diabetes Mellitus | - |
Colistimethate sodium (CMS) | Phase 3 | Bacterial Infections | - |
Acarbose | Phase 3 | Type 2 Diabetes Mellitus | - |
Fluorouracil (5-FU) | Phase 3 | Urinary Bladder Neoplasms | - |
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Phase 3 | HPV Infections | - |
2XP HEPTAVAX™-II SC | Phase 3 | Hepatitis B | - |
Abiraterone acetate | Phase 3 | Prostatic Neoplasms | - |
DOR | Phase 3 | HIV-1 Infection | - |
denufosol tetrasodium (INS37217) Inhalation Solution | Phase 3 | Cystic Fibrosis | - |
succinylcholine | Phase 3 | Neuromuscular Blockade | - |
MK-1084 | Phase 3 | Colon Adenocarcinoma | - |
peg-IFN | Phase 3 | Hepatitis C, Chronic | - |
MK1903 | Phase 2 | Dyslipidemia | - |
Ulevostinag | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - |
MK-5684 | Phase 2 | Malignant Neoplasm | - |
denufosol tetrasodium (INS37217) | Phase 2 | Cystic Fibrosis | - |
OPT-80 | Phase 2 | Diarrhea | - |
val-mCyd | Phase 2 | Chronic Hepatitis C | - |
Ertugliflozin 1 mg | Phase 2 | Diabetes Mellitus, Type 2 | - |
MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks | Phase 2 | Flushing | - |
M5049 low dose | Phase 2 | Systemic Lupus Erythematosus | - |
Dalotuzumab | Phase 2 | Carcinoma, Non-small-cell Lung | - |
MK-8777 | Phase 2 | Depression | - |
Everolimus | Phase 2 | Metastatic Breast Cancer | - |
Patritumab Deruxtecan | Phase 2 | Malignant Neoplasm | - |
ARQ 197 | Phase 2 | Pancreatic Neoplasms | - |
ridaforolimus (MK8669) | Phase 2 | Prostate Cancer | - |
ARQ 501 in combination with gemcitabine | Phase 2 | Pancreatic Cancer | - |
ARQ 501 | Phase 2 | Cancer | - |
Robatumumab | Phase 2 | Colorectal Cancer | - |
ADL5945 0.1 mg | Phase 2 | Opioid Induced Constipation | - |
MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks | Phase 2 | Diabetes Mellitus, Type II | - |
Donepezil | Phase 2 | Alzheimer's Disease | - |
M5717 330 mg | Phase 2 | Acute Malaria | - |
Pegylated Interferon Alfa | Phase 2 | Chronic Hepatitis C | - |
KW-3902IV | Phase 2 | Heart Failure, Congestive | - |
Favezelimab | Phase 2 | Advanced Non-Small Cell Lung Cancer | - |
tildrakizumab | Phase 2 | Psoriasis | - |
SCH 900538 | Phase 2 | Seasonal Allergic Rhinitis | - |
Vibostolimab | Phase 2 | Melanoma | - |
MK0493 | Phase 2 | Obesity | - |
MK0812 / Duration of Treatment: 12 Weeks | Phase 2 | Arthritis, Rheumatoid | - |
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months | Phase 2 | B-cell Lymphoma | - |
EBR/GZR FDC Tablet | Phase 2 | HCV Infection | - |
SCH 56592 | Phase 2 | Onychomycosis | - |
INS37217 Nasal Spray | Phase 2 | Perennial Allergic Rhinitis | - |
MK0916 | Phase 2 | Diabetes Mellitus, Type 2 | - |
MK0777 | Phase 2 | Generalized Anxiety Disorder | - |
MK0524A, /Duration of Treatment : 8 Weeks | Phase 2 | Flushing | - |
Gefapixant 100 mg | Phase 2 | Refractory Chronic Cough | - |
Cabazitaxel | Phase 2 | Prostatic Neoplasms, Castration-Resistant | - |
Uprifosbuvir | Phase 2 | Hepatitis C | - |
L-dopa | Phase 2 | Parkinson Disease | - |
MK0364 | Phase 2 | Obesity | - |
Pneumococcal Conjugate Vaccine (V114) | Phase 2 | Pneumococcal Infections | - |
Rolapitant Dose 1 | Phase 2 | Postoperative Nausea and Vomiting | - |
Single low dose cyclophosphamide | Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
V114 Aluminum-adjuvanted | Phase 2 | Pneumococcal Infections | - |
medroxyprogesterone acetate tablets OR megestrol acetate | Phase 2 | Endometrial Cancer | - |
Vibostolimab/Pembrolizumab | Phase 2 | Carcinoma, Renal Cell | - |
MK-8189 | Phase 2 | Schizophrenia, Acute Episode | - |
MK-3120 | Phase 2 | Urothelial Carcinoma | - |
MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks | Phase 2 | Type 2 Diabetes Mellitus | - |
Vicriviroc 30 mg | Phase 2 | HIV Infections | - |
Navarixin | Phase 2 | Solid Tumors | - |
Daptomycin for Injection | Phase 2 | Bacteremia | - |
valopicitabine | Phase 2 | Chronic Hepatitis C | - |
MK0677 | Phase 2 | Alzheimer's Disease | - |
UFOX + Cetuximab | Phase 2 | Previously Untreated Metastatic Colorectal Cancer | - |
Recombinant human growth hormone (r-hGH) | Phase 2 | Hypochondroplasia | - |
Ritonavir | Phase 2 | HIV Infections | - |
MK0359 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - |
Grazoprevir/Elbasvir FDC | Phase 2 | Hepatitis C | - |
Sofosbuvir | Phase 2 | Hepatitis C | - |
ARQ 197 plus erlotinib | Phase 2 | Metastatic Non-Small Cell Lung Cancer | - |
Raludotatug Deruxtecan (R-DXd) | Phase 2 | Gastrointestinal Cancer | - |
Stavudine | Phase 2 | HIV Infections | - |
Tepotinib | Phase 2 | Non-small Cell Lung Cancer | - |
MK0524 | Phase 2 | Seasonal Allergies | - |
MK-3795 | Phase 2 | VHL Gene Mutation | - |
Efprezimod alfa | Phase 2 | Graft Versus Host Disease | - |
boceprevir (SCH 503034) | Phase 2 | Chronic Hepatitis C | - |
MK0991, caspofungin acetate/Duration of Treatment: variable | Phase 2 | Candidiasis | - |
Posaconazole IV 6 mg/kg | Phase 2 | Invasive Fungal Infection | - |
Boserolimab | Phase 2 | Small Cell Lung Cancer | - |
V114 Lot 1 | Phase 2 | Pneumococcal Infections | - |
peginterferon alfa 2b | Phase 2 | Hepatitis C, Chronic | - |
TRUVADA® | Phase 2 | HIV Infections | - |
2 NRTIs | Phase 2 | Human Immunodeficiency Virus (HIV) Infection | - |
luspatercept | Phase 2 | B-Thalassemia | - |
Tulisokibart | Phase 2 | Hidradenitis Suppurativa | - |
PegIFN-2b | Phase 2 | HIV Infections | - |
TR701 FA | Phase 2 | Major Cutaneous Abscess | - |
TS-1 | Phase 2 | Gastric Cancer | - |
adavosertib | Phase 2 | Ovarian Cancer | - |
PegIntron (peginterferon alfa-2b) | Phase 2 | Hepatitis C, Chronic | - |
Relebactam 250 mg | Phase 2 | Intra-abdominal Infections | - |
Atorvastatin/niacin extended-release | Phase 2 | Carotid Atherosclerosis | - |
Antihistamine | Phase 2 | Esophageal Squamous Cell Carcinoma | - |
MK0249 | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | - |
Rebif | Phase 2 | Multiple Sclerosis | - |
MK-5442 | Phase 2 | Osteoporosis | - |
Oral testosterone undecanoate (Andriol) | Phase 2 | Hypogonadism | - |
Azithromycin ophthalmic solution, 1% | Phase 2 | Blepharitis | - |
Vorapaxar | Phase 2 | Atherosclerosis | - |
MK-8435 (Org 25935) 4-8 mg | Phase 2 | Schizophrenia | - |
Docetetaxel | Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
Rescue | Phase 2 | Type II Diabetes Mellitus | - |
Ceftolozane/Tazobactam | Phase 2 | Complicated Intra-Abdominal Infection | - |
MK-0873 | Phase 2 | Rheumatoid Arthritis | - |
Matuzumab | Phase 2 | Esophageal Cancer | - |
MK-6096 | Phase 2 | Migraine | - |
Pembrolizumab/vibostolimab coformulation | Phase 2 | Bladder Cancer | - |
PR51 (3, 10) | Phase 2 | Bacterial Infections; Virus Diseases | - |
V504 | Phase 2 | Cervical Cancer | - |
irinotecan hydrochloride | Phase 2 | Metastatic Colorectal Cancer | - |
Pertuzumab | Phase 2 | Breast Neoplasms | - |
epinastine 0.1% | Phase 2 | Allergic Rhinitis | - |
MK-0941 | Phase 2 | Type 2 Diabetes Mellitus | - |
imipenem/cilastatin 500 mg | Phase 2 | Urinary Tract Infections | - |
Recombinant human follicle stimulating hormone (r-hFSH) | Phase 2 | Infertility | - |
MK0518 | Phase 2 | HIV Infections | - |
Olaparib 400 mg | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - |
Ramucirumab | Phase 2 | Gastroesophageal Junction | - |
Vaniprevir 600 mg b.i.d. | Phase 2 | Hepatitis C, Chronic | - |
cetuximab, cisplatin | Phase 2 | Breast Neoplasm | - |
Interferon beta-1a | Phase 2 | Alzheimer's Disease | - |
ibuprofen | Phase 2 | Migraine | - |
V114 Medium Dose | Phase 2 | Pneumococcal Infections | - |
IDX719 | Phase 2 | Hepatitis C, Chronic | - |
V181 High-Potency Level | Phase 2 | Dengue Disease | - |
Itraconazole | Phase 2 | Chronic Hepatitis C | - |
Prednisolone | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - |
Biltricide (racemate praziquantel) oral tablets | Phase 2 | Schistosomiasis | - |
CXA-101/ tazobactam and metronidazole | Phase 2 | Complicated Intra-abdominal Infection | - |
Islatravir | Phase 2 | HIV-1 Infection | - |
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 2 | Infertility Implantation Failure | - |
Preladenant | Phase 2 | Parkinson Disease | - |
Sacituzumab Tirumotecan (sac-TMT) | Phase 2 | Gastroesophageal Junction | - |
Dalantercept plus sorafenib | Phase 2 | Advanced Adult Hepatocellular Carcinoma | - |
Pegylated Interferon (peg-IFN) | Phase 2 | Hepatitis C | - |
Nelfinavir mesylate | Phase 2 | HIV Infections | - |
Risperidone | Phase 2 | Schizophrenia | - |
Doravirine, Tenofovir, Lamivudine - Blinded | Phase 2 | HIV-1 | - |
MK2295 | Phase 2 | Pain, Postoperative | - |
V940 | Phase 2 | Squamous Non-small Cell Lung Cancer | - |
M5717 60 mg | Phase 2 | Malaria Infection | - |
R-DXD | Phase 2 | Lung Neoplasm | - |
Efinopegdutide | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease | - |
Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20 | Phase 2 | Papillomavirus Infections | - |
AR51 (12, 10) | Phase 2 | Bacterial Infections; Virus Diseases | - |
diphenhydramine | Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
MK0429 | Phase 2 | Post-Menopausal Osteoporosis | - |
Navarixin 10 mg | Phase 2 | Psoriasis | - |
Quavonlimab | Phase 2 | Advanced Solid Tumors | - |
Miransertib | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | - |
MK8141 | Phase 2 | Hypertension | - |
MK-1167 | Phase 2 | Alzheimer Disease | - |
SCH 530348 | Phase 2 | Arterial Obstructive Diseases | - |
MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks | Phase 2 | HIV Infections | - |
SCH 619734 | Phase 2 | Cough | - |
MK-0893 | Phase 2 | Diabetes Mellitus, Type 2 | - |
Epinastine Nasal Spray | Phase 2 | Seasonal Allergic Rhinitis | - |
Clesrovimab | Phase 2 | Respiratory Syncytial Viruses | - |
Ruzasvir | Phase 2 | Hepatitis C | - |
MK0686 | Phase 2 | Pain, Postoperative | - |
MK0822A | Phase 2 | Vitamin D Deficiency | - |
MK0633 | Phase 2 | Atherosclerosis | - |
ZA | Phase 2 | Breast Cancer | - |
Gefitinib | Phase 2 | Non-small Cell Lung Carcinoma | - |
Avelumab | Phase 2 | Squamous Non-Small Cell Lung Cancer | - |
MK-4830 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
L-756423 | Phase 2 | HIV Infections | - |
TR-701 200 mg | Phase 2 | Skin Diseases, Infectious | - |
timolol/dorzolamide combination | Phase 2 | Glaucoma | - |
MK-6213 | Phase 2 | Hypercholesterolemia | - |
zoster vaccine live (Oka/Merck) | Phase 2 | Shingles | - |
vinblastine | Phase 2 | Hodgkin Lymphoma | - |
Raludotatug Deruxtecan | Phase 2 | Ovarian Cancer Recurrent | - |
Esmeron® | Phase 2 | Neuromuscular Blockade | - |
MK-1029 150 mg | Phase 2 | Asthma | - |
VigantOL oil plus interferon beta-1a (Rebif) | Phase 2 | Relapsing-Remitting Multiple Sclerosis | - |
r-hFSH | Phase 2 | Infertility | - |
Coformulation favezelimab/pembrolizumab | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | - |
NM283 plus Peg-IFNα-2a | Phase 2 | Chronic Hepatitis C | - |
Lonafarnib | Phase 2 | Breast Cancer | - |
Gefapixant 50 mg | Phase 2 | Asthma | - |
Sitagliptin 25 mg | Phase 2 | Glucose Intolerance | - |
Letermovir oral granules | Phase 2 | Cytomegalovirus (CMV) Infection | - |
MK-2060 | Phase 2 | End-Stage Renal Disease | - |
IDX184 | Phase 2 | Chronic Hepatitis C Infection | - |
Pleconaril | Phase 2 | Asthma | - |
Gocatamig | Phase 2 | Small-Cell Lung Cancer | - |
ADL5859 30 mg | Phase 2 | Acute Pain | - |
Fosaprepitant | Phase 2 | Chemotherapy-induced Nausea and Vomiting | - |
MK3207- 2.5 mg | Phase 2 | Migraine | - |
MK-1200 | Phase 2 | Advanced Solid Tumors | - |
BCG | Phase 2 | Urinary Bladder Neoplasms | - |
teicoplanin | Phase 2 | Osteomyelitis | - |
Cilengitide 2000 mg once weekly | Phase 2 | Squamous Cell Cancer | - |
Gefapixant 45 mg | Phase 2 | Chronic Cough | - |
Farnesyl Protein Transferase Inhibitor | Phase 2 | Leukemia | - |
SCH 727965 | Phase 2 | Breast Neoplasms | - |
Palbociclib | Phase 2 | Renal Cell Carcinoma | - |
ADL5859 | Phase 2 | Peripheral Neuropathy | - |
MK2461 | Phase 2 | Neoplasm | - |
V114-A | Phase 2 | Pneumococcal Infections | - |
IFN beta 1a 44 mcg TIW | Phase 2 | Multiple Sclerosis | - |
Pegylated Liposomal Doxorubicin | Phase 2 | Breast Neoplasm | - |
S-1 | Phase 2 | Gastric Cancer | - |
MK0991, caspofungin acetate | Phase 2 | Aspergillosis | - |
SCH 486757 | Phase 2 | Cough | - |
Tecemotide (L-BLP25) | Phase 2 | Lung Neoplasms | - |
measles, mumps, and rubella virus vaccine live | Phase 2 | Measles | - |
Vicriviroc maleate | Phase 2 | HIV | - |
Tepotinib 300 mg | Phase 2 | Carcinoma, Hepatocellular | - |
SCH 900271 15mg | Phase 2 | Primary Hypercholesterolemia | - |
Vecuronium | Phase 2 | Anesthesia, General | - |
Avastin | Phase 2 | High-grade Serous Ovarian Carcinoma | - |
AS900672-Enriched 50 microgram (mcg) | Phase 2 | Infertility | - |
MK633 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - |
Atacicept | Phase 2 | Rheumatoid Arthritis | - |
Cilengitide | Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
Grazoprevir (GZR) | Phase 2 | Hepatitis C Virus | - |
Vibegron | Phase 2 | Urinary Bladder, Overactive | - |
Doxorubicin hydrochloride | Phase 2 | Breast Neoplasms | - |
ecallantide | Phase 2 | Bloodloss | - |
r-FSH | Phase 2 | Ovarian Stimulation | - |
Org 34517 | Phase 2 | Depression | - |
Enclitide Chloride | Phase 2 | Hypercholesterolemia | - |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate | Phase 2 | HIV-1 Infection | - |
Pembrolizumab (neoadjuvant) | Phase 2 | Lung Neoplasm Malignant | - |
ADL5945 0.25 mg | Phase 2 | Constipation | - |
Coformulated favezelimab/pembrolizumab | Phase 2 | Metastatic Urothelial Carcinoma | - |
I-DXd | Phase 2 | Esophageal Squamous Cell Carcinoma | - |
Regulatory & News
Approvals, filings, and latest developments